Elizabeth Hoge - 02 Apr 2026 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Reporting relationship: 10%+ Owner
Issuer ticker: RNAC
Reported as of: 02 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Apr 2026, 16:28:25 UTC
Prior SEC filing: 15 Oct 2024
Source filing: View source filing
Reporting owner signature: /s/ Murat Kalayoglu, Authorized Person

Key filing fact

Elizabeth Hoge filed Form 4 for Cartesian Therapeutics, Inc. (RNAC) on 06 Apr 2026.

Key facts

This page summarizes Elizabeth Hoge's Form 4 filing for Cartesian Therapeutics, Inc. (RNAC).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 06 Apr 2026, 16:28.

Change

Previous filing in this sequence was filed on 15 Oct 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0002000987 Primary reporting owner

Hoge Elizabeth

Relationship: 10%+ Owner
Address: C/O SOAR BIO, LLC, 7144 13TH PL NW, WASHINGTON
Signature: /s/ Murat Kalayoglu, Authorized Person
Signature date: 06 Apr 2026

CIK 0002000959

Seven One Eight Three Four Irrevocable Trust

Relationship: 10%+ Owner
Address: C/O SOAR BIO, LLC, 7144 13TH PL NW, WASHINGTON
Signature: /s/ Murat Kalayoglu, Authorized Person
Signature date: 06 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RNAC transaction

Common Stock

Options Exercise

Transaction value
Shares: +758,001
Change %: +17%
Price
Shares after: 5,313,261
Date: 02 Apr 2026
Ownership: as trustee
Footnotes: F1, F2

RNAC transaction

Common Stock

Options Exercise

Transaction value
Shares: +758,001
Change %: +17%
Price
Shares after: 5,313,261
Date: 02 Apr 2026
Ownership: as trustee
Footnotes: F1, F2

RNAC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 506,999
Date: 02 Apr 2026
Ownership: by spouse

RNAC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 506,999
Date: 02 Apr 2026
Ownership: by spouse

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RNAC transaction Derivative

Series A Non-Voting Convertible Preferred Stock

Options Exercise

Transaction value
Shares: -22,740
Change %: -40%
Price
Shares after: 33,662
Date: 02 Apr 2026
Ownership: as trustee
Underlying class: Common Stock
Underlying amount: 758,001
Exercise price
Footnotes: F1, F2, F3

RNAC transaction Derivative

Series A Non-Voting Convertible Preferred Stock

Options Exercise

Transaction value
Shares: -22,740
Change %: -40%
Price
Shares after: 33,662
Date: 02 Apr 2026
Ownership: as trustee
Underlying class: Common Stock
Underlying amount: 758,001
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On April 2, 2026, Seven One Eight Three Four Irrevocable Trust (the "Trust") elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation.

Footnote F2

Shares are held by the Trust. The reporting person is a trustee of the Trust.

Footnote F3

On November 13, 2023, the issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023 (the "Merger"). These securities represent merger consideration payable as a result of the closing of the Merger and securities purchased in a private placement in November 2023.